Angarus Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $9.7M
Latest Deal Amount
  • Investors
  • 3

Angarus Therapeutics General Information

Description

Developer of immuno-oncology therapies intended to respond to the urgent needs of cancer treatment. The company's therapies develop checkpoint blockers on the innate immunity STING pathway, that enhance the killing power of tumor-infiltrating lymphocytes and produce durable responses in a small fraction of terminal melanoma patients, enabling patients to get access to a wide range of cancer treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 428 Oakmead Parkway
  • Sunnyvale, CA 94085
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angarus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 22-Jun-2021 $9.7M 000.00 000.00 Completed Pre-Clinical Trials
1. Seed Round 000 000 0000 Completed
To view Angarus Therapeutics’s complete valuation and funding history, request access »

Angarus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Seed 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
To view Angarus Therapeutics’s complete cap table history, request access »

Angarus Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Nigel Ray Chief Executive Officer, President & Board Member
Randolph Johnson Ph.D Chief Scientific Officer
Chih-Ping Liu Ph.D Founder & Chairman
Lingyin Li Ph.D Scientific Co-Founder and Member of Scientific Advisory Board
Mark Smith Ph.D Scientific Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Angarus Therapeutics Board Members (5)

Name Representing Role Since
Chih-Ping Liu Ph.D Angarus Therapeutics Founder & Chairman 000 0000
Jean Liu JD Self Board Member 000 0000
Nigel Ray Angarus Therapeutics Chief Executive Officer, President & Board Member 000 0000
Peder Jensen MD Angarus Therapeutics Board Member 000 0000
Peter Langecker Ph.D Self Board Member 000 0000
To view Angarus Therapeutics’s complete board members history, request access »

Angarus Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Evolution VC Partners Venture Capital Minority 000 0000 000000 0
Foothill Ventures Venture Capital Minority 000 0000 000000 0
Sixth Borough Capital Management PE/Buyout Minority 000 0000 000000 0
To view Angarus Therapeutics’s complete investors history, request access »